Premium
Intravenous digoxin as a bioavailability standard
Author(s) -
Stoll Roger G.,
Wagner John G.,
Greenblatt David J.,
Duhme David W.,
Koch-Weser Jan,
Smith Thomas W.,
Tilstone W. J.,
Reavey P. C.
Publication year - 1975
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1975171117
Subject(s) - digoxin , bioavailability , viewpoints , medicine , pharmacology , administration (probate law) , intensive care medicine , political science , law , heart failure , art , visual arts
In a recent publication in this JOURNAL, Greenblatt and associates 3 recommended that the “administration of digoxin by slow infusion is preferable as an intravenous standard in bioavailability testing” as opposed to a rapid intravenous injection. While we do not necessarily disagree with this conclusion, we do disagree with the reasons cited in their publication to support this contention. Because of the likely influence an article such as this may have on federal regulatory procedures, we would like to express our alternative viewpoints as related to their study.